Neovascular
Sandoz Launches Afqlir (Aflibercept) in Europe, Increasing Access to Affordable Retinal Disease Treatment
Sandoz; Afqlir; aflibercept; biosimilar; retinal diseases; neovascular age-related macular degeneration (nAMD); European Commission approval; Eylea; anti-VEGF therapies; affordable treatment; vision loss; Europe
Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents
Bispecific antibodies, VEGF, neovascular age-related macular degeneration (nAMD), cancer therapy, clinical trials, royalty agreements.